In this context, it is noteworthy that single-agent administration of pembrolizumab (PD-1 antagonist) is now recommended by the US FDA and European Medicines Agency for the treatment of patients with advanced NSCLC who have a PD-L1 tumor promotion score (TPS) of ≥50% (27). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.